Vyome Announces New Board of Directors with Deep MIT and AI Ties
Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (
NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND.
